EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4

Chloe Carmichael, Irina Jouravskaya, Elizabeth Collins, Danielle Burns, Jiat Ling Poon, Helen Kitchen, Donna Mojdami, Madhumita Murphy, Nadia Ahmad, Chisom Kanu iD

The Patient - Patient-Centered Outcomes Research · 2025-05 · 18 (3) · 225-236

DOI: 10.1007/s40271-025-00730-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Patient - Patient-Centered Outcomes Research, online erschienen am 22.02.2025. Verfasst von Chloe Carmichael und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clarivate, London, UK. Hauptthemen laut MEDLINE: Obesity, Tirzepatide, Patient Satisfaction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, which was approved in 2023 by the US Food and Drug Administration for weight management in adults with obesity or overweight. The purpose of this study was to conduct qualitative exit interviews with participants who had participated in the SURMOUNT-4 clinical trial, to better understand the patient experience of tirzepatide. METHODS: Online exit interviews were conducted with adults from the USA who had participated in the SURMOUNT-4 clinical trial for weight management, recruited from 16 US-based SURMOUNT-4 clinical sites. Interviews utilized a semi-structured interview guide, and included questions related to receiving tirzepatide, using a single-use injection pen device, and the overall trial experience. Interviews were audio recorded and transcribed, and analyzed using a content analysis. RESULTS: Eighty-six adults (83% female; mean age 49.9 years) participated in the interviews. All participants shared at least one perceived benefit of tirzepatide experienced during the open-label phase of SURMOUNT-4, including improved appetite control, increased energy, or improved clothing fit. Despite the gastrointestinal side effects experienced, many participants liked the efficacy of tirzepatide, and reported that the single-use injection pen device for administering the study medication was easy to use. Most participants were willing to continue taking tirzepatide. CONCLUSIONS: Study findings showed that beyond the direct pharmacological effects of treatment with tirzepatide, participants reported a wide range of perceived improvements across several aspects of their lives. Participants also reported a few negative experiences, including side effects. It is possible that the participants who had a more positive experience were more inclined to participate in the exit interviews. This study highlights the value of exit interviews, which can provide more learning about patient experiences during a clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityTirzepatidePatient SatisfactionHumansFemaleMiddle AgedMaleAdultQualitative ResearchUnited StatesInterviews as TopicOverweightAged

Substanzen

Tirzepatide

Autor:innen und Institutionen

  • Clarivate, London, UK.
  • Eli Lilly and Company, Indianapolis, IN, 46285, USA.
  • Eli Lilly and Company, Indianapolis, IN, 46285, USA. kanu_chisom@lilly.com.

ORCID-Profile: Chisom Kanu

Förderung

  • Eli Lilly and Company

Zitieren

APA

Carmichael, C., Jouravskaya, I., Collins, E., Burns, D., Poon, J. L., Kitchen, H., Mojdami, D., Murphy, M., Ahmad, N., & Kanu, C. (2025). Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4. The Patient - Patient-Centered Outcomes Research, 18(3), 225-236. https://doi.org/10.1007/s40271-025-00730-0

Vancouver

Carmichael C, Jouravskaya I, Collins E, Burns D, Poon JL, Kitchen H, et al. Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4. The Patient - Patient-Centered Outcomes Research. 2025;18(3):225-236. doi:10.1007/s40271-025-00730-0

BibTeX
@article{Carmichael2025,
  author = {Carmichael, Chloe and Jouravskaya, Irina and Collins, Elizabeth and Burns, Danielle and Poon, Jiat Ling and Kitchen, Helen and Mojdami, Donna and Murphy, Madhumita and Ahmad, Nadia and Kanu, Chisom},
  title = {Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4},
  journal = {The Patient - Patient-Centered Outcomes Research},
  year = {2025},
  volume = {18},
  number = {3},
  pages = {225--236},
  doi = {10.1007/s40271-025-00730-0}
}
Kostenlos starten →